111, Inc.(YI)Earnings, Financials & Key Ratios
YI•NASDAQ
$4.32
Price updated Jul 2, 2026
About111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. As of December 31, 2021, it operated 14 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan provinces. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.Show more
- Revenue$12.21B-15.2%
- EBITDA$2M-90.5%
- Net Income-$17M+74.0%
- EPS (Diluted)-7.42+1.3%
- Gross Margin5.76%
- EBITDA Margin0.01%-88.8%
- Operating Margin-0.08%-658.5%
- Net Margin-0.14%+69.3%
- ROE-5.66%+71.3%
YI Price & Volume
111, Inc. (YI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction and Negative Equity Profile
Investment Thesis • Updated 2025Q2
VerdictNegative: The company's inability to generate consistent net income
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Structural margin compression risk
Key Thesis Takeaways
- 111, Inc.
- faces significant structural headwinds as its high-volume, low-margin pharmaceutical distribution model struggles to achieve meaningful operating leverage, evidenced by a 0.0% operating margin in 2025Q2.
- The company's financial position is further complicated by a persistent negative equity balance of -$673.1M, which raises substantial concerns regarding long-term solvency and capital sustainability.
- Investors should remain cautious as the firm continues to navigate revenue declines and erratic cash flow conversion, which may necessitate further external financing to maintain operations.
Verdict Logic
evidenced by a -0.6% net margin in 2025Q2, combined with a precarious negative equity position, suggests a high risk of continued capital erosion.
YI Growth Metrics
111, Inc. (YI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years8.29%
3 Years-3.32%
TTM-3.69%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM77.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM78.07%
Return on Capital
10 Years-38.08%
5 Years-32.35%
3 Years-22.15%
Last Year-2.9%
Peers Comparison
Key metrics vs top competitors for 111, Inc. (YI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.32 | $37.74M | -3.96 | -15.19% | -0.14% | -5.66% | — | |
| $37.57 | $8.25B | 73.67 | 59% | -0.56% | -2.48% | — | |
| $9.10 | $1.64B | -7.98 | -1.54% | -6.81% | -12.37% | — | |
| $28.26 | $2.34B | 128.45 | -10.86% | -2.42% | -1.59% | — | |
| $2.86 | $1.07B | -116.73 | 64.4% | -0.98% | -0.18% | — | |
| $6.08 | $114.09M | 22.52 | 18.78% | 6.37% | 5.47% | — |
Compare YI vs Peers
111, Inc. (YI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when YI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
YI Frequently Asked Questions
111, Inc. (YI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is 111, Inc.'s revenue?
111, Inc. (YI) reported $14.18B in revenue for fiscal year 2025. This represents a 1523% increase from $873.8M in 2016.
How fast is 111, Inc. growing?
111, Inc. (YI) saw revenue decline by 15.2% over the past year.
Is YI profitable?
111, Inc. (YI) reported a net loss of $74.1M for fiscal year 2025.
Dividend & Returns
What is YI's return on equity?
111, Inc. (YI) has a return on equity (ROE) of -5.7%. Negative ROE indicates the company is unprofitable.
What is 111, Inc.'s free cash flow?
111, Inc. (YI) generated $97.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.